Pfizer → Allergan
A $160bn deal structured almost entirely for its tax address. Killed by a US Treasury memo issued twelve days before signing became irreversible.
Abandoned in April 2016, two days after the US Treasury tightened the rules on the tax inversions that underpinned it.
- Value
- $160B
- Announced
- November 2015
- Outcome
- Terminated
- Sector
- Pharma
- Deal type
- merger
- Acquirer
- Pfizer (United States)
- Target
- Allergan (Ireland)
Why it mattered
Pfizer's US statutory rate was 35%; Allergan's Irish rate was 12.5%. The transaction was engineered as a reverse merger — smaller Allergan the nominal buyer, larger Pfizer the target — precisely so the combined entity would inherit Ireland as its tax domicile. Estimated annual tax savings ran well over $1bn.
The story
Announced November 2015, the transaction was flagged by the Obama administration as the standing example of everything wrong with the inversion loophole. On 4 April 2016 the US Treasury issued a new rule specifically targeting "serial inverters" — Allergan, which had itself been assembled through prior inversions, met the test almost by name. The economics collapsed inside 48 hours. Pfizer terminated on 6 April and paid Allergan the $150m break fee.
What it left behind
The template for a regulator killing a deal by writing new rules mid-negotiation. Every large cross-border pharma deal signed since carries a "material change in law" clause that names the Pfizer–Allergan collapse as the reason it exists.
At a glance
- Structure
- Reverse merger, tax inversion
- Announced
- 23 Nov 2015
- Terminated
- 6 Apr 2016
- Cause of death
- US Treasury & IRS rule
- Break fee paid
- $150M
- Reimbursed expenses
- $400M+
- Estimated annual tax saving lost
- $1B+